Background: In the phase III double-blind Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2, apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in moderate to severe psoriasis.
Limitations: Baseline randomization was not stratified for nail/scalp psoriasis. Key words: apremilast; nail psoriasis; phosphodiesterase 4 inhibitor; psoriasis; scalp psoriasis; systemic therapy.
Conclusion
Psoriasis is a chronic, systemic inflammatory disease with a prevalence as high as 3.1% in the United States. 1 In patients with psoriasis, dysregulation of the immune response is thought to result in a chronic imbalance in the production of proinflammatory and anti-inflammatory cytokines. [2] [3] [4] Available therapies suppress inflammatory responses or target specific mediators implicated in the pathogenesis of psoriasis. However, long-term use of these therapies is often compromised by variable efficacy, safety, and tolerability issues, or need for administration via injection or infusion. 5, 6 Dermatologic signs and symptoms of psoriasis often occur in difficult-to-treat areas such as the nails and scalp. Nail involvement occurs in approximately 50% of patients with plaque psoriasis, with a lifetime incidence of 80% to 90% [7] [8] [9] ; scalp involvement affects up to 80% of patients with psoriasis. 10, 11 Involvement of these difficult-to-treat areas may have particularly detrimental effects on patient quality of life. 7, [10] [11] [12] Treatment of nail and scalp psoriasis with topical therapy is often challenging because of the poor diffusion into the nail tissue and the inaccessibility of scalp lesions. 8, 11 Patient satisfaction and compliance with current treatment modalities for nail and scalp psoriasis are often low because of difficulties in administration to the scalp, poor compliance, and inadequate long-term efficacy. [13] [14] [15] Cyclic adenosine monophosphate is a key modulator of immune cell responses, and its levels are regulated by phosphodiesterase 4. 16 Apremilast, an oral phosphodiesterase 4 inhibitor, increases intracellular cyclic adenosine monophosphate levels, thus regulating production of proinflammatory and anti-inflammatory mediators. 17 Apremilast was approved by the US Food and Drug Administration in 2014 and by the European Commission in 2015 for the treatment of adult patients with active psoriatic arthritis and for patients with moderate to severe plaque psoriasis. 18, 19 The approval of apremilast for psoriasis was based on the findings of the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) phase III clinical trial program, comprising 2 multicenter, randomized, placebo-controlled studies that evaluated the efficacy, safety, and tolerability of apremilast in adults with moderate to severe plaque psoriasis. The efficacy of apremilast in patients with nail and scalp psoriasis over 16 weeks of treatment has been reported. 20, 21 This report describes the efficacy of apremilast in the subsets of patients from the phase III ESTEEM trials with nail psoriasis and moderate to very severe scalp psoriasis with up to 52 weeks of treatment.
METHODS
Study design and participants ESTEEM 1 and 2 were similarly designed phase III, multicenter, randomized, double-blind, placebocontrolled studies of apremilast 30 mg twice daily (BID) in patients with moderate to severe plaque psoriasis (Fig 1) . Full details of the study design, inclusion and exclusion criteria, patient population, and primary safety and efficacy results for ESTEEM 1 and 2 have been described previously. 20, 21 Nail and scalp assessments Nail and scalp assessments were made in all patients at baseline using the Nail Psoriasis Severity Index (NAPSI) and Scalp Physician Global Assessment (ScPGA). NAPSI is a composite score of physician assessment of nail psoriasis 22 ; a target nail was used to assess nail involvement, if nail involvement (NAPSI score $1) was present at baseline. Target nail NAPSI scores range from 0 to 8; higher scores indicate greater severity, and a decrease in NAPSI score indicates improvement. The target thumbnail or fingernail that represented the worst nail psoriasis at baseline was assessed. Nail assessments included the percent change from baseline in
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d Nail and scalp psoriasis negatively impact patient quality of life. Apremilast 30 mg twice daily significantly reduced the severity of nail and scalp psoriasis at week 16; these improvements were sustained over time. Apremilast is a viable oral treatment option for patients with difficult-to-treat nail or scalp psoriasis.
NAPSI score in the target nail and the proportion of patients who achieved at least a 50% reduction from baseline in target nail NAPSI score (NAPSI-50), and the change from baseline in the number of involved nails in patients with nail psoriasis. NAPSI information was collected at baseline and weeks 16, 24, 32, 40, and 52. The ScPGA was used to assess scalp involvement, in patients with a score of 3 or greater at baseline. The ScPGA scale ranges from 0 (clear) to 5 (very severe). ScPGA scores were collected at baseline and weeks 2, 4, 8, 12, and 16, then every 8 weeks up to weeks 40 and 52.
Patients provided written informed consent before study-related procedures were performed, and the protocol and consent were approved by institutional review boards or ethics committees at all investigational sites. The studies were conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki.
Statistical analysis
Efficacy was assessed using the full analysis set in patients who had nail psoriasis (NAPSI score $1) at baseline and moderate to very severe scalp psoriasis (ScPGA score $3) at baseline. Discrete variables (NAPSI-50, ScPGA score 0 or 1) were analyzed using a x 2 test. For continuous variables (eg, percent change from baseline in NAPSI score), the analysis of covariance model with treatment as a factor and baseline value as a covariate was used. All statistical significance was compared using the 2-sided 0.05 alpha level. Missing data were handled with the last observation carried forward methodology. In addition, improvements in nail bed and nail matrix using the full analysis set were summarized descriptively.
RESULTS

Patients
The full analysis set included 844 patients from ESTEEM 1 (placebo: n = 282; apremilast 30 mg BID: n = 562) and 411 patients from ESTEEM 2 (placebo: n = 137; apremilast 30 mg BID: n = 274). At baseline, 558 (66.1%) patients in ESTEEM 1 and 266 (64.7%) patients in ESTEEM 2 had nail psoriasis (target nail NAPSI score $1), and 563 (66.7%) patients and 269 (65.5%) patients from these respective studies had moderate to very severe scalp psoriasis (ScPGA score $3). Demographic and baseline characteristics were appropriately balanced between the placebo and apremilast 30 mg BID groups among patients with nail or scalp psoriasis (Tables I and II) .
Results for period A (placebo-controlled phase; weeks 0-16)
In both ESTEEM 1 and ESTEEM 2, NAPSI improvements (ie, decreases) at week 16 were significantly greater in patients treated with apremilast 30 mg BID versus placebo; the mean percent change in NAPSI score was À22.5% (ESTEEM 1; P \ .0001) and À29.0% (ESTEEM 2; P = .0052) with apremilast versus 16.5% (ESTEEM 1) and À7.1% (ESTEEM 2) with placebo ( Fig 2, A and B). As shown in Fig 2, C, a greater improvement from baseline in target nail NAPSI score was associated with increasing Psoriasis Area and Severity Index (PASI) response across different PASI response categories (PASI score categories: \50, 50 to \75, 75 to \90, $90). At week 16, a significantly greater proportion of patients in the apremilast 30 mg BID group also achieved a NAPSI-50 response compared with the placebo group in each study (33.3% vs 14.9%, ESTEEM 1; 44.6% vs 18.7%, ESTEEM 2; P \ .0001 both studies). A decrease from baseline in the mean number of involved nails (mean baseline value: 6-7 nails) occurred in the apremilast 30 mg BID group at week 16 (mean change in number of nails involved, ESTEEM 1: 0.7; ESTEEM 2: 1.3). In comparison, the number of involved nails in the placebo group was essentially unchanged from baseline to week 16 in both studies (mean change, ESTEEM 1: 0.1; ESTEEM 2: 0.4). Nail bed and nail matrix scores also improved with apremilast 30 mg BID versus placebo at week 16 in both ESTEEM 1 and ESTEEM 2 (Table III) .
Among patients with moderate to very severe scalp psoriasis (ScPGA score $3) at baseline, achievement of ScPGA score of 0 (clear) or 1 (minimal) at week 16 was significantly greater in patients taking apremilast 30 mg BID versus placebo (46.5% vs 17.5% ESTEEM 1; 40.9% vs 17.2% ESTEEM 2; P \.0001 for both) (Fig 3) Nail Psoriasis Severity Index NAPSI-50: 50% reduction from baseline in target nail Psoriasis Severity Index score PASI:
Psoriasis Area and Severity Index ScPGA:
Scalp Physician Global Assessment sPGA:
static Physician Global Assessment
Results for period B (weeks 16-32) Among patients with nail psoriasis at baseline, those who were randomized to apremilast 30 mg BID at baseline continued to show improvement in NAPSI score at week 32 (ESTEEM 1: À43.6%; ESTEEM 2: À60.0%) (Fig 2, A and B) . Patients initially randomized to placebo who were switched to apremilast 30 mg BID at week 16 showed improvements during period B, similar to those seen in apremilast patients during period A (Fig 2, A and B) . Patients who did not achieve a PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2) response at week 32 were able to add topicals and/or ultraviolet (UV) B therapy at week 32 at the discretion of the investigator. Blinding was maintained until all patients discontinued or completed their week 52 visit. BID, Twice daily. The n reflects the number of randomized patients; actual number of patients available for each parameter may vary. Data for patients with nail psoriasis include patients with target nail NAPSI score $1. BID, Twice daily; BSA, body surface area; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index; sPGA static Physician Global Assessment.
At week 32, the mean percent change from baseline in NAPSI score for these patients was À24.6% and À47.6% in ESTEEM 1 and ESTEEM 2, respectively. The proportion of patients achieving NAPSI-50 response also increased during period B in patients who continued on apremilast 30 mg BID (ESTEEM 1: 45.2%; ESTEEM 2: 55.4%) and in those who switched from placebo to apremilast 30 mg BID (ESTEEM 1: 34.9%; ESTEEM 2: 52.0%). The number of involved nails and nail bed/matrix scores decreased further from weeks 16 to 32 in patients who continued on apremilast 30 mg BID, and started to decrease among placebo patients after the switch to apremilast 30 mg BID (Table III) . Improvement in scalp involvement was generally sustained through week 32 among patients initially randomized to apremilast 30 mg BID at baseline; 140 (37.4%) and 57 (32.4%) patients in ESTEEM 1 and ESTEEM 2, respectively, achieved ScPGA score of 0 or 1 at week 32. Among patients initially randomized to placebo who switched to apremilast at week 16, 71 (43.6%) and 36 (50.7%) patients in ESTEEM 1 and ESTEEM 2, respectively, achieved an improvement in ScPGA score to 0 or 1 at week 32.
Results for period C (weeks 32-52): PASI responders
In both ESTEEM 1 and ESTEEM 2, continued improvement in nail psoriasis occurred through week 52 in PASI responders, which included those patients initially randomized to apremilast 30 mg BID or placebo at baseline who had a PASI response (ESTEEM 1: $ 75% reduction from baseline in PASI score/ESTEEM 2: $ 50% reduction from baseline in PASI score) at week 32 and continued to receive apremilast through week 52 (period C) (Fig 5, A and  B) . At week 52, the mean percent reduction from baseline in target nail NAPSI score in these patients was approximately 60% to 64%. Among PASI responders, NAPSI-50 achievement in ESTEEM 1 and ESTEEM 2 was also generally maintained with apremilast for up to 52 weeks, regardless of initial randomization to apremilast 30 mg BID (70.7% and 68.6%, respectively) or placebo (64.1% and 69.0%, respectively) at baseline. Similarly, among patients with ScPGA score of 3 or greater at baseline, achievement of ScPGA score of 0 or 1 was also maintained with apremilast in both studies at week 52 among PASI responders, regardless of assignment to apremilast 30 mg BID (83. 
DISCUSSION
Although the nails and scalp account for a small percentage of the body surface area, psoriasis in these areas can have a disproportionate effect on a patient's physical and psychosocial function. 7, 13 Evidence of the efficacy of available therapies in these difficultto-treat areas is limited, underscoring the need for further clinical evaluation and new treatment options. 23, 24 In the ESTEEM 1 and ESTEEM 2 studies, nail psoriasis and moderate to very severe scalp psoriasis were present at baseline in approximately two thirds of patients, emphasizing the prevalence of this difficult-to-treat form in patients with moderate to severe psoriasis. The analyses of the ESTEEM studies demonstrate that apremilast 30 mg BID significantly improves nail and scalp psoriasis. Improvement in nail psoriasis achieved during the placebo-controlled phase continued through week 32 with apremilast 30 mg BID. These improvements were sustained in patients who had a PASI response at week 32 and continued taking apremilast 30 mg BID through week 52. Nail psoriasis is particularly difficult to treat and may be triggered by an inflammatory response as part of the Koebner phenomenon in patients with moderate to severe chronic plaque psoriasis. 24, 25 Clinical practice recommendations for the treatment of nail psoriasis, published by the Medical Board of the National Psoriasis Foundation, recommend systemic therapies, including apremilast, for patients with significant skin and nail disease or skin, nail, and joint disease. 8 Improvements in nail psoriasis tend to lag behind improvements in skin and joint symptoms, given the time it takes for fingernails to grow out (ie, 3-4 mm/mo, or 5-7 months for growth from the nail matrix to the distal fingertip), such that longer clinical trials are needed to demonstrate effects on nail psoriasis. 8 In ESTEEM, improvements in both nail bed and nail matrix disease were noted with apremilast treatment versus placebo at week 16; improvements continued through week 32 and were maintained through week 52. Missing values at week 16 were imputed using the last observation carried forward (LOCF ) methodology. Patients without an observation at week 32 were considered nonresponders. *P \.0001 versus placebo in ESTEEM 1 and *P = .0052 vs placebo in ESTEEM 2, both based on the x 2 test. PASI-50, $ 50% reduction from baseline in PASI score; PASI-75, $ 75% reduction from baseline in PASI score; PASI-90, $ 90% reduction from baseline in PASI score. Studies of systemic therapies for the treatment of scalp psoriasis are limited. Currently, topical vitamin D analogs and corticosteroids are typically used to treat scalp psoriasis, but the long-term effectiveness of these agents is often limited by nonadherence because of the poor cosmetic properties of some topicals and/ or difficulty with application.
14 In ESTEEM 1 and 2, more than 40% of the patients with moderate to very severe scalp disease at baseline achieved ScPGA score of 0 or 1 by week 16 with apremilast 30 mg BID, and this improvement was generally maintained through week 32. In addition, among patients who achieved a PASI response at week 32 and continued taking apremilast 30 mg BID, the majority had ScPGA score of 0 or 1 after 1 year of treatment.
Apremilast was generally well tolerated in the ESTEEM studies. 20, 21, 26 Most adverse events were mild or moderate in severity. The exposure-adjusted incidence rate of adverse events did not appear to increase over time, and no new significant adverse events emerged with continued apremilast exposure. Changes in laboratory parameters were transient, with no trends observed. Although providing clinically useful information, the analyses reported here from the ESTEEM studies were limited by the fact that initial randomization was not stratified by subgroups of patients with nail and scalp psoriasis to ensure balance between treatment groups. However, baseline characteristics among patients with nail psoriasis and scalp psoriasis appeared similar between treatment groups in both ESTEEM 1 and ESTEEM 2, such that this was unlikely to have substantially impacted the results. In conclusion, apremilast 30 mg BID significantly reduced the severity of nail and scalp psoriasis. Improvements in nail and scalp psoriasis were sustained over time. Thus, our findings indicate that apremilast, a novel oral therapeutic option for patients with moderate to severe plaque psoriasis, is an effective option for patients with nail and/or scalp involvement.
